Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

KNOXVILLE, Tenn., Nov. 19, 2024 /PRNewswire/ -- Novoxel Inc. announces the U.S. FDA clearance of the Tixel i (pronounced "Tixel Eye") for sale in the USA. The newest member of the Tixel family of ...

Symptoms of ocular rosacea may include only “a dry, gritty feel” to the eye and a red eyelid margin, according to ...

Experts warn that rising air pollution levels can lead to serious eye diseases, including dry eye disease and inflammation. Discover how pollutants affect your eyes and what you can do to protect your ...

Dr. Cornelia Peterson is dedicated to finding treatments for cancer by researching tumors that develop in Meibomian glands, ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Welcome to Tarsus’ Third Quarter 2024 Financial Results ...

broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across ...

Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

In addition to XDEMVY (lotilaner ophthalmic solution) 0.25%, which is FDA approved in the United States for the treatment of Demodex blepharitis, Tarsus is also investigating TP-03 for the treatment ...

Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme ...